XML 113 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net deferred tax position (Tables)
 12 Months Ended
Dec. 31, 2023
Income Taxes [Abstract]  
Summary of Net Deferred Tax Position
An analysis of the net deferred tax position is set forth below:
(€ million)202320222021
Deferred taxes on:
Consolidation adjustments (intragroup margin in inventory)1,525 1,388 1,292 
Provision for pensions and other employee benefits853 850 1,117 
Remeasurement of other acquired intangible assets
(2,904)
(a)
(3,269)(3,079)
Recognition of acquired property, plant and equipment at fair value(21)(24)(26)
Equity interests in subsidiaries and investments in other entities(b)
(1,023)(617)(590)
Tax losses available for carry-forward1,526 1,506 1,516 
Stock options and other share-based payments84 92 88 
Accrued expenses and provisions deductible at the time of payment(c)
1,994 1,859 1,585 
Other(d)
2,536 1,755 1,078 
Net deferred tax asset/(liability)4,570 3,540 2,981 
(a)    As of December 31, 2023, includes remeasurements of the acquired intangible assets of Bioverativ (€1,241 million), Principia (€610 million), Ablynx (€204 million), Genzyme (€50 million) and Amunix (€109 million).
(b)    In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately €60.4 billion) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2023, Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December 31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October 2023 (see Note D.30.).
(c)    Includes deferred tax assets related to restructuring provisions, amounting to €286 million as of December 31, 2023, €256 million as of December 31, 2022, and €226 million as of December 31, 2021.
(d)    Includes deferred taxes arising on the spread tax deduction of R&D expenses, amounting to €1,331 million as of December 31, 2023 and €742 million as of December 31, 2022.
Summary of Tax Losses Available for Carry-forward
The table below shows when tax losses available for carry-forward are due to expire:
(€ million)
Tax losses available for carry-forward(a)
20246 
20257 
202634 
202723 
2028126 
2029 and later8,737 
Total as of December 31, 20238,933 
Total as of December 31, 20228,503 
Total as of December 31, 20217,644 
(a)    Excluding tax loss carry-forwards on asset disposals. Such carry-forwards amounted to €5 million as of December 31, 2023, €5 million as of December 31, 2022 and €5 million as of December 31, 2021.